Jinhai Med Tech (02225.HK) Surges Over 15% Amid Launch of AI-Enabled Navigated Spinal Endoscopy Innovation with Medtronic at CIIE

According to the Zhitong Finance APP, Jinhai Medical Technology (02225) surged over 15% during trading, and as of press time, it rose by 5.04%, reaching 1.25 Hong Kong dollars, with a turnover of 12.1974 million Hong Kong dollars.

On the news front, the 8th China International Import Expo (CIIE) was held in Shanghai from November 5 to 10. Jin Hai Medical Technology previously announced that during the 8th CIIE, its subsidiary Jin Hai Medical would jointly release the latest innovative navigation-guided endoscopic spine technology developed in collaboration with Medtronic China's Orthopedics and Neurosurgery Business Group (Medtronic China). This technology is expected to be applicable in spinal surgeries, paving a new path for the precision and intelligent development of spinal procedures. It aims to shorten the learning curve for clinicians in mastering endoscopic spine techniques and promote more efficient and widespread clinical applications in the future.

It is reported that Medtronic's main businesses cover the research, development, manufacturing, distribution, and sales of device-based medical therapies and services in the fields of cardiovascular diseases, neuroscience, medical surgery, and diabetes. Medtronic has production bases in Shanghai, Changzhou, and Chengdu, China. Since the first China International Import Expo (CIIE) in 2018, Medtronic has participated in the CIIE for seven consecutive years, leveraging the expo's strong influence to showcase and accelerate the application of its latest innovative medical technologies and products.